Mentzer Index in breast cancer: Insights into anemia and tumor progression - a narrative review.

Anemia is a prevalent condition in breast cancer patients, often linked to factors such as chemotherapy, nutritional deficiencies, and tumor-related inflammation. The Mentzer Index, traditionally used to differentiate iron deficiency anemia from thalassemia, has recently gained attention as a tool for diagnosing and managing anemia in oncology. This review explores the application of the Mentzer Index in breast cancer, highlighting its potential role in identifying the underlying causes of anemia and guiding treatment strategies. By assessing the Mentzer Index, clinicians can better understand the nature of anemia in breast cancer patients, which may ultimately improve prognosis and treatment outcomes. The relationship between anemia and tumor progression in breast cancer is complex, with anemia often signaling more aggressive disease and poor prognosis. Iron deficiency, as identified by an elevated Mentzer Index, may exacerbate tumor hypoxia, fostering conditions that promote tumor cell proliferation and metastasis. Conversely, anemia caused by chronic inflammation or cancer-induced suppression of erythropoiesis may further impair immune function and contribute to treatment resistance. The Mentzer Index provides valuable insights into these mechanisms, aiding clinicians in making informed decisions regarding anemia management and its potential impact on tumor dynamics.